Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: November 13, 2006
Last updated: October 14, 2009
Last verified: October 2009
A randomized, controlled, open-label multicenter trial to assess the safety and efficacy of 3 oxaliplatin-fluoropyrimidine containing regimens (mFOLFOX6; bFOL; XELOX) + Bevacizumab (TREE1 and TREE2) as first line therapy of advanced metastatic colorectal cancer.

Condition Intervention Phase
Colorectal Cancer
Drug: oxaliplatin
Drug: fluoropyrimidine
Drug: bevacizumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Prospective Study Comparing Three Regimens of Oxaliplatin Plus Fluoropyrimidine and Avastin for Evaluation of Safety and Tolerability in First-line Treatment of Patients With Advanced Colorectal Cancer.

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • To evaluate the safety and efficacy of three oxaliplatin-fluoropyrimidine regimens when combined with bevacizumab as therapy for previously untreated metastatic colorectal cancer (TREE 2)

Secondary Outcome Measures:
  • The overall incidence of grade 3 and grade 4 adverse events during the first 12 weeks of treatment for each of the oxaliplatin-fluoropyrimidine regimens used without bevacizumab (TREE1)
  • Type, frequency, severity, timing, and relatedness of all adverse events during treatment and for 30 days following discontinuation of treatment for each of the oxaliplatin-fluoropyrimidine regimens when used with or without bevacizumab(TREE1 and TREE2)
  • Actual treatment administration as characterized by median, mean, and range of doses given; dose modifications, omissions, and delays; and actual and relative dose intensity (TREE1 and TREE2)
  • Tumor response rate (overall and confirmed) based on application of the Response Evaluation Criteria in Solid Tumors (RECIST) (TREE1 and TREE2)
  • Time to treatment failure (TTF) (TREE1 and TREE2)
  • Time to tumor progression (TTP) (TREE1 and TREE2)
  • Median survival (TREE1 and TREE2)
  • A randomized, controlled, open-label multicenter trial to assess the safety & efficacy of 3 oxaliplatin-fluoropyrimidine containing regimens (mFOLFOX6; bFOL; XELOX) +Avastin (TREE1 & TREE2) as first line therapy of advanced metastatic colorectal cancer
  • Patients enrolled prior to the initiation of Amendment 3 (TREE1) will not be eligible to receive Avastin as a component of their treatment regimen.

Estimated Enrollment: 373
Study Start Date: November 2002
Estimated Study Completion Date: June 2005

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.


Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

  1. Histologically documented adenocarcinoma of the colon, rectum or appendix.
  2. Metastatic/recurrent disease not amenable to potentially curative treatment (e.g., inoperable metastatic disease).
  3. No prior chemotherapy for metastatic/recurrent disease. Prior adjuvant treatment with 5-FU/LV and/or IFL is allowed if it is completed at least 6 months before study registration.
  4. ECOG Performance Status 0- 1.
  5. At least one unidimensionally measurable lesion with a diameter >/= 20 mm using conventional CT or MRI scans or >/= 10 mm using spiral CT scans. If a single lesion is identified as the target lesion, a histological or cytological confirmation of adenocarcinoma is required.
  6. Recovery in full from any previous surgical procedure.
  7. No other serious concomitant disease.
  8. Required baseline laboratory parameters:

    1. Absolute neutrophil count (ANC) >/=1,500/mm3 (standard international [SI] units 109/L);
    2. Platelets >/= 100,000/mm3 (SI units 109/L);
    3. Hemoglobin >/= 8.0 g/dL (SI units mmol/L);
    4. Creatinine </= 1.5 x ULN; Total bilirubin </= 2.0 x ULN;
    5. Serum glutamate-oxalate transferase (SGOT, AST) Serum glutamic pyruvic transaminase (SGPT, ALT) </= 3 x ULN </= 3 x ULN;
    6. Urinalysis - dipstick Protein < +1;
    7. Coagulation PT/PTT (INR) Within Normal Limits for Institution;
    8. Serum pregnancy test for females of childbearing potential: Negative within 7 calendar days of randomization to study


The presence of any of the following will exclude a subject from study enrollment:

  1. Prior treatment with oxaliplatin or bevacizumab.
  2. Any uncontrolled infection.
  3. History of myocardial infarction within the previous 6 months or current clinical evidence of congestive heart failure, non-stable coronary artery disease, clinically significant hypertension (blood pressure of >160/110 mmHg on medication), or symptomatic peripheral vascular disease.
  4. History of any other cancer (except non melanoma skin cancer or carcinoma in-situ of the cervix) unless in complete remission and off all therapy for that cancer for at least 5 years.
  5. Central nervous system metastases.
  6. Peripheral neuropathy of any cause.
  7. Pregnant or lactating women.
  8. Hypersensitivity to one of the study drugs or ingredients.
  9. Participation in any investigational drug study within 4 weeks preceding enrollment.
  10. Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome.
  11. Medical or psychiatric disorders that would interfere with informed consent, compliance or make them a poor risk for participation in this trial.
  12. Patients with known DPD deficiency.
  13. Patients with interstitial pneumonia or extensive symptomatic fibrosis of the lungs.
  14. Patients with calculated creatinine clearance of <30 ml/min using Cockroft and Gault formula.
  15. Patients who have received an organ allograft.
  16. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study entry.
  17. Chronic, daily treatment with aspirin (>325 mg/day) or nonsteroidal anti-inflammatory medications (intermittent or "p.r.n." use for pain is permitted).
  18. Evidence of a bleeding diathesis or coagulopathy.
  19. Subjects found to have proteinuria at baseline - If patients are found to have >/= 1+ proteinuria at baseline screening they should undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate <2g of protein/24 hr to allow participation in the study.
  20. Patients on chronic therapeutic Warfarin therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00399750

United States, New Jersey
Bridgewater, New Jersey, United States, 08807
Sponsors and Collaborators
Study Director: Yasir Nagarwala, M.D. Sanofi
  More Information Identifier: NCT00399750     History of Changes
Other Study ID Numbers: L_8851
Study First Received: November 13, 2006
Last Updated: October 14, 2009

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on April 26, 2017